British health regulator NICE has issued a final draft rejecting the prescription of breast cancer drug eribulin
![Advanced Breast Cancer Drug Eribulin Rejected by NICE Advanced Breast Cancer Drug Eribulin Rejected by NICE](https://images.medindia.net/health-images/1200_1000/breast-cancer-recurrence.jpg)
“Although the evidence presented to the independent advisory committee indicated that eribulin may help some patients live for a little longer, it also caused more undesirable side effects than other treatments already available, and the effects on health-related quality of life had not been adequately assessed”, chief executive of NICE, Sir Andrew Dillon said.
Source-Medindia